MA’s Alnylam Pharmaceuticals Reports New Company Structure; To Split Into Three Units
Alnylam Pharmaceuticals announced its new pipeline growth strategy, which will be split into three units. The new strategy will focus on development and commercialization of RNAi therapeutics in three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease. CEO John Maraganore believes that these three units will, “address major unmet needs in a wide range of diseases with high-impact, differentiated medicines, and continue to build what we believe to be one of the most robust pipelines in biotech.”
